Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment
Theresia M. Westers(Vrije Universiteit Amsterdam), Arjan A. van de Loosdrecht(Dutch Cancer Society), Corien Eeltink(Vrije Universiteit Amsterdam), Maurice J. D. L. van der Vorst(Vrije Universiteit Amsterdam), Gert J. Ossenkoppele(Dutch Cancer Society), Canan Alhan(Vrije Universiteit Amsterdam), Martine E.D. Chamuleau(Hovon)
Cited by 92
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k